-
Security Type
-
Convertible Note
-
Min Investment
-
$100
-
Offering Date
-
October 08, 2020
-
Expected Close Date
-
February 21, 2021
-
Target Raise
-
$50.00K-$15.00M
-
Deal Notes
-
Price per Share: $3.00
Interest: 6%
Discount: 20%
Company Description
We translate cutting edge research into practical diagnostic solutions for some of the most crucial public health issues facing the world today. Specifically, we have been early pioneers in identifying and developing epigenetic biomarkers in saliva, focusing on non-coding RNA and the microbiome. In addition to recently launching the first ever epigenetic saliva test for autism, we are currently working on developing similar tests for Parkinson's disease, concussion, and Anorexia nervosa.
Key Deal Facts
We have just launched the world's first saliva test for autism.
We have raised over $30 million from private investors and have received nearly $3 million in research grants.
We are developing a robust pipeline of products including tests for Parkinson's disease, concussion, Anorexia Nervosa, and schizophrenia.
The members of our management team and clinical advisory board are recognized leaders in autism and epigenetic research.
We have filed 29 patent applications for biomarker panels/diagnostic methods, and 34 trademark applications in the US and internationally.
We are one of 7 companies in the U.S. selected to participate in the NIH's 2019-2020 Regulatory/Reimbursement Training Track CAP program.
We are one of the global leaders in the development of epigenetic diagnostic tools for neurological conditions.
Use of Proceeds
$50,000
- 15% towards marketing costs and legal and accounting fees
- 3% towards Wefunder fees; remainder for general corporate purposes
$1,070,000
- 10% towards marketing costs and legal and accounting fees
- 3% towards Wefunder fees; remainder for general corporate purposes
Management Team / Advisory Board Bios
Richard Uhlig
CEO and Founder
More than 25 years of business experience focused on the design and development of innovative products across various industries. Former CEO of Morgan Stanley Bank and CIO at Merrill Lynch Bank. Graduate of Cornell University.
Benjamin Perry
President
Over 10 years of experience in the software development industry, with deep experience in cloud computing architecture, blockchain technology, and agile product management. Graduate of Cornell University.
Richard Bongo
Chief Financial Officer
Over 30 years of experience in structured finance, Managing Director at one of Europe’s largest banks, positions at multiple Wall Street firms such as Lehman Brothers, Credit Suisse, Merrill Lynch and Bank of America. Graduate of Kings College.
Deal Notes
Price per Share: $3.00
Interest: 6%
Discount: 20%
